Amunix Announces Appointment of Dr. Angie You as Chief Executive Officer and Dr. Rich Heyman as Chairman of the Board of Directors
MOUNTAIN VIEW, Calif. – January 3, 2019 – Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics, today announced the appointment of Angie You, Ph.D., as Chief Executive Officer, and Rich Heyman, Ph.D., as Chairman of the Board of Directors.
“I am delighted to welcome Angie and Rich to the Amunix team. Having successfully partnered to build Aragon Pharmaceuticals, Angie and Rich bring a wealth of drug development and business expertise, which will help drive the company’s next phase of growth,” said Amunix co-founder, President, and Chief Technology Officer Volker Schellenberger, Ph.D. “In addition, the entire Amunix team is excited that Frazier Life Sciences has acquired a majority position in Amunix. As part of this transaction, I am pleased to welcome Frazier Managing General Partners Patrick Heron and Jamie Topper to the Amunix board. The Frazier Life Sciences team has a long track record of building successful biotechnology companies and their involvement is a testament to the team and company we are building together,” continued Dr. Schellenberger.
About Dr. Angie You, Chief Executive Officer
Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology (NASDAQ: SRRA), a publicly listed hematology and oncology drug development company, where she helped the company through a successful initial public offering that raised over $150 million. She also led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, human resources, and business development. At Aragon, Dr. You helped raise two successful rounds of financing totaling $90 million as well as the business development process that resulted in the company’s acquisition by Johnson & Johnson for an upfront payment of $650 million and up to $350 million in contingent milestone payments. Dr. You also served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals.
Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College.
About Dr. Rich Heyman, Chairman of the Board of Directors
Dr. Rich Heyman is an accomplished scientist and biopharma executive with over 25 years of experience leading innovative biotechnology companies. Dr. Heyman previously served as Chief Executive Officer of Seragon Pharmaceuticals, a company focused on drugs targeting hormone dependent cancers that was acquired by Roche for an upfront payment of $725 million and up to $1 billion in contingent milestone payments. Dr. Heyman was also the co-founder and Chief Executive Officer of Aragon Pharmaceuticals, which was acquired for a total consideration of up to $1 billion by Johnson & Johnson. Prior to Aragon, Dr. Heyman held leading scientific and business roles at several biotechnology companies, including X-Ceptor Therapeutics and Ligand Pharmaceuticals. At Ligand, Dr. Heyman led the development of Panretin® and Targretin®, which were approved by the FDA for the treatment of cancer.
In addition to serving on the Amunix Pharmaceuticals Board of Directors, Dr. Heyman is a Director at Gritstone Oncology, Yumanity Therapeutics, Metacrine Inc., Vividion Therapeutics, Mavupharma, and ORIC Pharmaceuticals. He is also the Vice Chairman of The Salk Institute and author or inventor of more than 120 publications and patents. Dr. Heyman was an NIH postdoctoral fellow at the Salk Institute and received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.
About Amunix Pharmaceuticals
Amunix Pharmaceuticals, based in Mountain View, CA, is a privately held drug discovery and development company with two proprietary technologies, XTEN® and ProTIA, that enable the rapid generation of protein therapeutics that are engineered to be fit for purpose. The company’s goal is to leverage its protein engineering platform and know-how to discover and develop safe and effective therapeutics for patients with cancer and other serious diseases. Amunix’s robust technology platforms have been validated through multiple collaborations with leading biopharmaceutical companies including Celgene, Genentech, Janssen, Roche, Bioverativ, and Baxter.
For additional information about the company, please visit www.amunix.com.
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.2 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.
For more information about Frazier Healthcare Partners, visit the company’s website at www.frazierhealthcare.com.
Volker Schellenberger, Ph.D.
President and CTO